Hualan Biological Engineering's (SHE:002007) unit, Hualan Gene Engineering, received a drug registration certificate from the Chinese drug administration for bevacizumab injection, according to a Shenzhen Stock Exchange disclosure on Friday.
The certificate for the cancer drug is valid until Nov. 14, 2029, the biopharmaceutical company said.
The company's shares closed 4% lower.